FDA to approve expanded access for rare disease drugs within 90 days

With Makary gone, the FDA will prioritize rare disease drug approvals to address investor concerns over unpredictable regulatory decisions. Industry lobbying and patient advocacy groups will push for faster pathways, likely leading to concrete action.

Implied probability (Yes)

72%